Cargando…
Therapeutic Implementation of Oncolytic Viruses for Cancer Immunotherapy: Review of Challenges and Current Clinical Trials
The development of cancer therapeutics has evolved from general targets with radiation and chemotherapy and shifted toward treatments with a more specific mechanism of action such as small molecule kinase inhibitors, monoclonal antibodies against tumor antigens, or checkpoint inhibitors. Recently, o...
Autores principales: | Wang, X, Maeng, HM, Lee, J, Xie, C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647850/ https://www.ncbi.nlm.nih.gov/pubmed/36381110 http://dx.doi.org/10.36266/JBSR/164 |
Ejemplares similares
-
Oncolytic viruses as immunotherapy: progress and remaining challenges
por: Aurelian, Laure
Publicado: (2016) -
Oncolytic Virus Immunotherapy
por: Marchini, Antonio, et al.
Publicado: (2021) -
The Clinical Advances of Oncolytic Viruses in Cancer Immunotherapy
por: Zolaly, Mohammed A, et al.
Publicado: (2023) -
Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review
por: Li, Mengyuan, et al.
Publicado: (2023) -
Fusogenic Viruses in Oncolytic Immunotherapy
por: Krabbe, Teresa, et al.
Publicado: (2018)